Do analysts recommend ACHV or MOR?

Achieve Life Sciences currently has a consensus target price of $15.00, suggesting a potential upside of 85.19%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Achieve Life Sciences is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achieve Life Sciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to ACHV or SUPN?

In the previous week, Supernus Pharmaceuticals had 6 more articles in the media than Achieve Life Sciences. MarketBeat recorded 12 mentions for Supernus Pharmaceuticals and 6 mentions for Achieve Life Sciences. Supernus Pharmaceuticals' average media sentiment score of 1.39 beat Achieve Life Sciences' score of 1.33 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, TRVI or ACHV?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A

Is TRVI or ACHV more profitable?

Trevi Therapeutics' return on equity of -23.59% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -23.59% -22.64% Achieve Life Sciences N/A -511.12% -82.35%

Does the media favor TRVI or ACHV?

In the previous week, Trevi Therapeutics had 3 more articles in the media than Achieve Life Sciences. MarketBeat recorded 9 mentions for Trevi Therapeutics and 6 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 1.33 beat Trevi Therapeutics' score of 1.22 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Achieve Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ACHV or RGC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is ACHV or RGC more profitable?

Regencell Bioscience's return on equity of 0.00% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -511.12% -82.35% Regencell Bioscience N/A N/A N/A

Achieve Life Sciences (ACHV) Competitors

$8.10 -0.08 (-0.98%)

As of 08/28/2026 04:00 PM Eastern

Compare

ACHV vs. MOR, SUPN, ATAI, TRVI, and RGC

Should you buy Achieve Life Sciences stock or one of its competitors? Achieve Life Sciences's main competitors and comparable companies include MorphoSys (MOR), Supernus Pharmaceuticals (SUPN), Atai Beckley (ATAI), Trevi Therapeutics (TRVI), and Regencell Bioscience (RGC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Achieve Life Sciences compare to MorphoSys?

Achieve Life Sciences (NASDAQ:ACHV) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Achieve Life Sciences currently has a consensus target price of $15.00, suggesting a potential upside of 85.19%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Achieve Life Sciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Achieve Life Sciences has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 1.8% of Achieve Life Sciences shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Achieve Life Sciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Achieve Life Sciences' return on equity of -511.12% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
MorphoSys	-226.79%	-694.31%	-22.55%

Achieve Life Sciences has a beta of 2.24, meaning that its share price is 124% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

In the previous week, Achieve Life Sciences had 6 more articles in the media than MorphoSys. MarketBeat recorded 6 mentions for Achieve Life Sciences and 0 mentions for MorphoSys. Achieve Life Sciences' average media sentiment score of 1.33 beat MorphoSys' score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Achieve Life Sciences	Positive
MorphoSys	Neutral

Summary

Achieve Life Sciences beats MorphoSys on 14 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Supernus Pharmaceuticals?

Achieve Life Sciences (NASDAQ:ACHV) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

In the previous week, Supernus Pharmaceuticals had 6 more articles in the media than Achieve Life Sciences. MarketBeat recorded 12 mentions for Supernus Pharmaceuticals and 6 mentions for Achieve Life Sciences. Supernus Pharmaceuticals' average media sentiment score of 1.39 beat Achieve Life Sciences' score of 1.33 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Achieve Life Sciences has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

33.5% of Achieve Life Sciences shares are held by institutional investors. 1.8% of Achieve Life Sciences shares are held by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has higher revenue and earnings than Achieve Life Sciences. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
Supernus Pharmaceuticals	$718.95M	3.54	-$38.55M	-$1.92	N/A

Achieve Life Sciences currently has a consensus price target of $15.00, indicating a potential upside of 85.19%. Supernus Pharmaceuticals has a consensus price target of $62.83, indicating a potential upside of 43.68%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Achieve Life Sciences is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Achieve Life Sciences has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Summary

Achieve Life Sciences beats Supernus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Atai Beckley?

Achieve Life Sciences (NASDAQ:ACHV) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

In the previous week, Achieve Life Sciences had 5 more articles in the media than Atai Beckley. MarketBeat recorded 6 mentions for Achieve Life Sciences and 1 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 1.87 beat Achieve Life Sciences' score of 1.33 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Overall Sentiment
Achieve Life Sciences	Positive
Atai Beckley	Very Positive

Achieve Life Sciences has higher earnings, but lower revenue than Atai Beckley. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
Atai Beckley	$4.09M	661.02	-$660.05M	-$2.18	N/A

Achieve Life Sciences presently has a consensus target price of $15.00, indicating a potential upside of 85.19%. Atai Beckley has a consensus target price of $10.56, indicating a potential upside of 44.80%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Achieve Life Sciences is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by company insiders. Comparatively, 19.8% of Atai Beckley shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Achieve Life Sciences has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

Achieve Life Sciences has a net margin of 0.00% compared to Atai Beckley's net margin of -14,938.36%. Atai Beckley's return on equity of -88.30% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
Atai Beckley	-14,938.36%	-88.30%	-58.88%

Summary

Achieve Life Sciences beats Atai Beckley on 10 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Achieve Life Sciences (NASDAQ:ACHV) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

Trevi Therapeutics' return on equity of -23.59% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Achieve Life Sciences	N/A	-511.12%	-82.35%

Trevi Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market.

In the previous week, Trevi Therapeutics had 3 more articles in the media than Achieve Life Sciences. MarketBeat recorded 9 mentions for Trevi Therapeutics and 6 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 1.33 beat Trevi Therapeutics' score of 1.22 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics presently has a consensus price target of $27.08, suggesting a potential upside of 61.31%. Achieve Life Sciences has a consensus price target of $15.00, suggesting a potential upside of 85.19%. Given Achieve Life Sciences' higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Trevi Therapeutics beats Achieve Life Sciences on 8 of the 12 factors compared between the two stocks.

How does Achieve Life Sciences compare to Regencell Bioscience?

Achieve Life Sciences (NASDAQ:ACHV) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 1.8% of Achieve Life Sciences shares are held by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Regencell Bioscience's return on equity of 0.00% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
Regencell Bioscience	N/A	N/A	N/A

In the previous week, Achieve Life Sciences had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 6 mentions for Achieve Life Sciences and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.87 beat Achieve Life Sciences' score of 1.33 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Achieve Life Sciences	Positive
Regencell Bioscience	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Achieve Life Sciences currently has a consensus price target of $15.00, indicating a potential upside of 85.19%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Achieve Life Sciences is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Achieve Life Sciences has a beta of 2.24, meaning that its share price is 124% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

Summary

Achieve Life Sciences beats Regencell Bioscience on 7 of the 12 factors compared between the two stocks.

Get Achieve Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACHV vs. The Competition

Export

Metric	Achieve Life Sciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$833.51M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-5.23	787.65	273.16	25.45
Price / Sales	N/A	793.10	604.48	76.58
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	-57.86	11.97	12.98	6.14
Net Income	-$54.65M	$2.83B	$3.48B	$348.86M
7 Day Performance	1.38%	0.39%	0.13%	-0.80%
1 Month Performance	28.57%	5.34%	7.08%	4.13%
1 Year Performance	171.81%	6.05%	24.67%	15.17%

Achieve Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACHV Achieve Life Sciences	3.2364 of 5 stars	$8.10 -1.0%	$15.00 +85.2%	+171.8%	$833.51M	N/A	N/A	20
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
SUPN Supernus Pharmaceuticals	4.5444 of 5 stars	$49.01 +1.5%	$62.83 +28.2%	-3.1%	$2.85B	$718.95M	N/A	580	Positive News
ATAI Atai Beckley	3.7001 of 5 stars	$7.27 +0.3%	$10.56 +45.3%	+59.2%	$2.69B	$4.09M	N/A	80	Positive News
TRVI Trevi Therapeutics	3.4572 of 5 stars	$18.57 +0.5%	$27.08 +45.9%	+131.3%	$2.64B	N/A	N/A	20	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACHV) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Achieve Life Sciences (ACHV) Competitors

ACHV vs. MOR, SUPN, ATAI, TRVI, and RGC

How does Achieve Life Sciences compare to MorphoSys?

Summary

How does Achieve Life Sciences compare to Supernus Pharmaceuticals?

Summary

How does Achieve Life Sciences compare to Atai Beckley?

Summary

How does Achieve Life Sciences compare to Trevi Therapeutics?

Summary

How does Achieve Life Sciences compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Achieve Life Sciences (ACHV) Competitors

ACHV vs. MOR, SUPN, ATAI, TRVI, and RGC

How does Achieve Life Sciences compare to MorphoSys?

Do analysts recommend ACHV or MOR?

Which has preferable valuation & earnings, ACHV or MOR?

Do insiders and institutionals believe in ACHV or MOR?

Is ACHV or MOR more profitable?

Which has more risk & volatility, ACHV or MOR?

Does the media prefer ACHV or MOR?

Summary

How does Achieve Life Sciences compare to Supernus Pharmaceuticals?

Does the media refer more to ACHV or SUPN?

Which has more risk and volatility, ACHV or SUPN?

Do institutionals and insiders have more ownership in ACHV or SUPN?

Which has preferable earnings & valuation, ACHV or SUPN?

Do analysts recommend ACHV or SUPN?

Is ACHV or SUPN more profitable?

Summary

How does Achieve Life Sciences compare to Atai Beckley?

Does the media prefer ACHV or ATAI?

Which has better valuation and earnings, ACHV or ATAI?

Do analysts rate ACHV or ATAI?

Do insiders and institutionals have more ownership in ACHV or ATAI?

Which has more volatility & risk, ACHV or ATAI?

Is ACHV or ATAI more profitable?

Summary

How does Achieve Life Sciences compare to Trevi Therapeutics?

Which has preferable valuation and earnings, TRVI or ACHV?

Is TRVI or ACHV more profitable?

Which has more risk & volatility, TRVI or ACHV?

Does the media favor TRVI or ACHV?

Do analysts recommend TRVI or ACHV?

Do institutionals & insiders hold more shares of TRVI or ACHV?

Summary

How does Achieve Life Sciences compare to Regencell Bioscience?

Do institutionals and insiders believe in ACHV or RGC?

Is ACHV or RGC more profitable?

Does the media refer more to ACHV or RGC?

Which has better valuation & earnings, ACHV or RGC?

Do analysts rate ACHV or RGC?

Which has more risk & volatility, ACHV or RGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools